Hyperbaric oxygen therapy is FDA-cleared and UHMS-approved for one bone condition: refractory osteomyelitis. It is also a mainstay of osteoradionecrosis care. For uncomplicated fractures, the 2012 Cochrane review found no randomized trials that met its inclusion criteria, so the evidence does not support routine use. HBOT helps most where bone is infected, irradiated, or poorly vascularized.
Bone is living tissue with a complex blood supply, and its ability to heal depends on adequate oxygen delivery. When bone is fractured, infected, or reconstructed, healing can stall if oxygen supply is inadequate. HBOT has an established role in a few specific bone situations and is FDA-cleared for one of them. This is where it helps, where it does not, and what the evidence actually shows.
Why does bone healing depend on oxygen?
Bone regeneration is an oxygen-intensive process. Osteoblasts (bone-forming cells) need oxygen for collagen synthesis and mineralization. Angiogenesis, the growth of new blood vessels into the healing callus, depends on VEGF signaling that requires adequate oxygen gradients. Immune cells clearing infection or dead bone need high oxygen for their oxidative killing mechanisms.
When any of these steps is oxygen-limited, whether from impaired circulation, radiation damage, infection, or extensive bone loss, healing slows or fails. HBOT addresses this by raising tissue oxygen far above what normal circulation can deliver. In a mouse fracture model, Kawada and colleagues (2013) showed that hyperbaric hyperoxia accelerated fracture healing, evidence that supports the biological rationale even though it has not been confirmed in human fractures.
Which bone conditions does HBOT actually treat?
HBOT’s bone uses cluster around infected, irradiated, and poorly vascularized bone. It is an adjunct, used alongside surgery and antibiotics, not a standalone treatment.
HBOT for bone conditions: role, evidence, and status
| Bone condition | HBOT role | Evidence strength | FDA/UHMS status |
|---|---|---|---|
| Refractory osteomyelitis | Adjunct after surgical debridement | Moderate-Strong | Approved |
| Osteoradionecrosis | Cornerstone treatment and prevention | Moderate | Approved |
| Non-union fracture | Adjunct after fixation surgery | Emerging | Off-label |
| Compromised bone grafts | Perioperative support | Emerging | Off-label |
| Early avascular necrosis | Investigational, pre-collapse | Limited | Off-label |
Osteomyelitis: the strongest evidence
Chronic osteomyelitis, infection of bone, is HBOT’s clearest bone indication. Infected bone is typically ischemic: bacteria, biofilm, and destruction of the blood supply combine to create profoundly hypoxic tissue that resists both immune clearance and antibiotics. HBOT works through several mechanisms: direct toxicity to anaerobic bacteria, restoration of neutrophil oxidative killing in ischemic tissue, improved antibiotic penetration, and stimulation of angiogenesis to rebuild the vascular supply. It is used as an adjunct following surgical debridement. UHMS recognizes refractory osteomyelitis as an approved indication, supported by consistent retrospective series rather than large randomized trials. The HBOT and infections article covers the infection-specific mechanisms.
Osteoradionecrosis
When bone in a radiation field loses its blood supply and dies, osteoradionecrosis (ORN) results, most commonly in the jaw after head and neck radiation. HBOT is a cornerstone of ORN management, both for treating established ORN and for preventing it before dental procedures in irradiated jaw tissue. The standard protocol involves 20 sessions before surgical intervention and 10 after, as recommended by the UHMS. The broader context is in the radiation damage article.
Fracture healing and non-union
Standard uncomplicated fractures in healthy patients heal through a well-orchestrated process that does not require HBOT. The 2012 Cochrane review by Bennett and colleagues set out to assess HBOT for delayed healing and established non-union and found that no randomized controlled trials met its inclusion criteria, meaning there is no trial-level evidence to support routine use. Where HBOT has more rationale is in specific challenging cases: non-union after surgery, fractures in diabetic patients with compromised vascularity, open fractures with extensive soft-tissue damage, and fractures in previously irradiated bone. In those settings the same oxygen-delivery problem HBOT addresses in wound healing is present, and the animal data (Kawada, 2013) is consistent, but human proof is still missing. Athletes with stress fractures often ask about it, a topic in the HBOT for athletes guide.
Bone grafts and avascular necrosis
Bone grafts must revascularize to integrate, and in compromised tissue beds (previously irradiated or poorly vascularized diabetic tissue) that revascularization is impaired. HBOT has been used perioperatively to improve the tissue bed and support graft integration, though the evidence is limited to case series and retrospective data. In early avascular necrosis (bone death from interrupted blood supply, often in the femoral head), HBOT has been studied before structural collapse, with some benefit reported in early stages and less in advanced disease. It is not a standard AVN treatment but remains an area of interest for early-stage disease when surgery is being deferred. A 2025 review by Feng and colleagues surveys these bone applications and their evidence base.
What reduces HBOT’s effect on bone healing?
Smoking significantly impairs HBOT’s angiogenic effects and is strongly associated with worse outcomes in osteoradionecrosis and osteomyelitis. Diabetes adds complexity: the vascular impairment that makes diabetic patients candidates for HBOT also reduces its absolute effectiveness, so aggressive diabetes management alongside treatment improves results.
Orthopedic hardware is rarely a barrier. Standard screws, plates, rods, and nails are titanium or stainless-steel alloys that are not affected by chamber pressure and are not ferromagnetic, unlike in MRI. Any implanted device should still be disclosed to the hyperbaric physician. For patients being treated for osteomyelitis or ORN, response is tracked with imaging (plain films, CT, and MRI each show different aspects of healing) plus clinical measures such as pain, local inflammatory signs, and lab values like ESR and CRP. The post-surgery recovery and ligament repair articles cover related musculoskeletal healing applications.
Frequently Asked Questions
How many HBOT sessions are needed for osteomyelitis?
Protocols typically involve 40 to 60 sessions, used following surgical debridement and alongside prolonged antibiotic therapy. The number depends on the extent and chronicity of the infection, the amount of bone involved, and the patient’s response. HBOT is an adjunct in refractory osteomyelitis, not a standalone cure, and it is used specifically when infection persists despite adequate surgery and antibiotics.
Can HBOT heal a non-union fracture without surgery?
Unlikely for established non-unions, and the 2012 Cochrane review found no randomized trials supporting HBOT for fracture non-union. Non-unions typically require surgical intervention (fixation revision, bone grafting) to create the biological and mechanical environment for healing. HBOT may support healing after such surgery in compromised patients, but it is not a substitute for the surgery itself.
Is HBOT covered by insurance for osteomyelitis?
Yes, when criteria are met. HBOT for refractory osteomyelitis is an approved indication covered by Medicare and most commercial insurers, with documentation of refractory infection despite adequate antibiotics and use following appropriate surgery. Prior authorization is required. The insurance coverage guide covers the process, and the cost guide provides context if coverage is partial or denied.
What is refractory osteomyelitis?
Refractory osteomyelitis is bone infection that has failed to respond to adequate antibiotic therapy and surgical debridement, with persistent signs of infection despite appropriate treatment. This distinction matters for insurance, because HBOT coverage for osteomyelitis generally requires documented treatment refractoriness rather than a first-line infection that has not yet been treated conventionally.
Sources
- Bennett MH, Stanford RE, Turner R. “Hyperbaric oxygen therapy for promoting fracture healing and treating fracture non-union.” Cochrane Database of Systematic Reviews, 2012. PMID 23152225 (doi.org/10.1002/14651858.CD004712.pub4)
- Kawada S, et al. “Hyperbaric Hyperoxia Accelerates Fracture Healing in Mice.” PLoS ONE, 2013. doi.org/10.1371/journal.pone.0072603
- Feng J, et al. “Hyperbaric Oxygen Therapy for the Treatment of Bone-Related Diseases.” International Journal of Molecular Sciences, 2025. PMID 39940834
- Undersea and Hyperbaric Medical Society. “Indications for Hyperbaric Oxygen Therapy” (refractory osteomyelitis; osteoradionecrosis). uhms.org
- Mayo Clinic. “Hyperbaric oxygen therapy.” mayoclinic.org
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
